Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)
Roger von Moos(Kantonsspital Graubünden), Arnoud J. Templeton(University of Basel), A.C. Fuhrer(Swiss Group For Clinical Cancer Research), Andreas Müller, T Wehrhahn(Kantonsspital Aarau), Sandro Anchisi(Hôpital du Valais), Hanne Hawle(Swiss Group For Clinical Cancer Research), Urs Huber(Klinik Hirslanden), Martin Zweifel(Spitalzentrum Centre hospitalier Biel- Bienne), Richard Cathomas(Kantonsspital Graubünden), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), C. Schär(Swiss Group For Clinical Cancer Research), Thomas Hermanns(University of Cologne), Olivia Pagani(Swiss Group For Clinical Cancer Research), Sabine Schmid(University of Bern), Mathias K. Fehr(Breast Center), Priska Bützberger(Kantonsspital Baden), Daniel Rauch(Washington University in St. Louis), Susanna Stoll(Triemli Hospital), Silke Gillessen(Institute of Oncology Research)
Cited by 4
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k